Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. announced that the company has been issued a patent by the United States Patent and Trademark Office with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension associated with HFpEF.